News articles about Inogen (NASDAQ:INGN) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Inogen earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the medical technology company an impact score of 45.2550060678639 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s rankings:
INGN has been the topic of several analyst reports. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a research note on Tuesday, January 9th. BidaskClub upgraded Inogen from a “hold” rating to a “buy” rating in a research note on Saturday. Leerink Swann reissued an “outperform” rating and issued a $120.00 price target (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Finally, Needham & Company LLC raised their price target on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Four investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $103.29.
Inogen (NASDAQ:INGN) traded up $0.73 during trading on Monday, hitting $117.41. The stock had a trading volume of 118,792 shares, compared to its average volume of 135,241. The stock has a market capitalization of $2,435.15, a PE ratio of 95.46, a PEG ratio of 3.96 and a beta of 1.02. Inogen has a 1-year low of $66.51 and a 1-year high of $130.05.
In other Inogen news, insider Scott Wilkinson sold 30,651 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $115.75, for a total value of $3,547,853.25. Following the completion of the sale, the insider now directly owns 38,107 shares in the company, valued at approximately $4,410,885.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Byron Myers sold 35,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $116.77, for a total value of $4,086,950.00. Following the completion of the sale, the executive vice president now owns 48,600 shares of the company’s stock, valued at $5,675,022. The disclosure for this sale can be found here. Insiders sold 111,151 shares of company stock valued at $13,018,588 over the last 90 days. Company insiders own 5.31% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/inogen-ingn-earning-somewhat-favorable-media-coverage-report-finds.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.